These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 36611797)
61. Lysis with Saponin improves detection of the response through CD203c and CD63 in the basophil activation test after crosslinking of the high affinity IgE receptor FcepsilonRI. Hoffmann HJ; Bøgebjerg M; Nielsen LP; Dahl R Clin Mol Allergy; 2005 Jul; 3():10. PubMed ID: 15996266 [TBL] [Abstract][Full Text] [Related]
62. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML. Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157 [TBL] [Abstract][Full Text] [Related]
63. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Français de Cytogénétique Hématologique. Martiat P; Michaux JL; Rodhain J Blood; 1991 Jul; 78(1):205-11. PubMed ID: 2070054 [TBL] [Abstract][Full Text] [Related]
64. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601 [No Abstract] [Full Text] [Related]
65. Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells. Prado-Carrillo O; Arenas-Ramírez A; Llaguno-Munive M; Jurado R; Pérez-Rojas J; Cervera-Ceballos E; Garcia-Lopez P Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887063 [TBL] [Abstract][Full Text] [Related]
76. [Detection of phosphotyrosine in chronic myeloid leukemia cells with PY20 antibody and its clinical applications]. Tian J; Cheng H; Xu KL; Pan XY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):1056-60. PubMed ID: 19698259 [TBL] [Abstract][Full Text] [Related]
77. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. Carlo-Stella C; Regazzi E; Sammarelli G; Colla S; Garau D; Gazit A; Savoldo B; Cilloni D; Tabilio A; Levitzki A; Rizzoli V Blood; 1999 Jun; 93(11):3973-82. PubMed ID: 10339507 [TBL] [Abstract][Full Text] [Related]
78. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842 [TBL] [Abstract][Full Text] [Related]
79. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia. Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669 [TBL] [Abstract][Full Text] [Related]